Postoperative Adjuvant Chemotherapy Improves Survival in Stage II Colon Cancer ? A Propensity Score Matching Analysis

Objective: The use of postoperative adjuvant chemotherapy (POAC) after surgery for patients with stage II colon cancer remains controversial. The current study was conducted to investigate the effectiveness of POAC using propensity score (PS) matching analysis based on prognostic factors.Materials:...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Juntendo Iji Zasshi = Juntendo Medical Journal 2016, Vol.62(6), pp.463-471
Hauptverfasser: SUGIMOTO, KIICHI, SAKAMOTO, KAZUHIRO, NIWA, KOICHIRO, ISHIYAMA, SHUN, KAMIYAMA, HIROHIKO, KOMIYAMA, HIROMITSU, TAKAHASHI, MAKOTO, KOJIMA, YUTAKA, GOTO, MICHITOSHI, TOMIKI, YUICHI
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 471
container_issue 6
container_start_page 463
container_title Juntendo Iji Zasshi = Juntendo Medical Journal
container_volume 62
creator SUGIMOTO, KIICHI
SAKAMOTO, KAZUHIRO
NIWA, KOICHIRO
ISHIYAMA, SHUN
KAMIYAMA, HIROHIKO
KOMIYAMA, HIROMITSU
TAKAHASHI, MAKOTO
KOJIMA, YUTAKA
GOTO, MICHITOSHI
TOMIKI, YUICHI
description Objective: The use of postoperative adjuvant chemotherapy (POAC) after surgery for patients with stage II colon cancer remains controversial. The current study was conducted to investigate the effectiveness of POAC using propensity score (PS) matching analysis based on prognostic factors.Materials: Two hundred and nineteen patients with stage II colon cancer who underwent surgery with curative intent between 1995 and 2005 were enrolled.Methods: PS matching analysis was used to adjust for differences in clinicopathological severity between the patients with and without POAC.Results: Before PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.76, 95%CI; 0.40-1.45, p=0.41) or cancer-specific survival (Hazard ratio=0.52, 95%CI; 0.22-1.19, p=0.12). After PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.55, 95%CI; 0.23-1.23, p=0.15) or cancer-specific survival (Hazard ratio=0.46, 95%CI; 0.16-1.18, p=0.11).Conclusion: The one-to-one pair PS matching successfully balanced the clinicopathological factors between the patients with and without POAC. The PS matching analysis demonstrated no significant difference in survival in the patients with stage II colon cancer.
doi_str_mv 10.14789/jmj.62.463
format Article
fullrecord <record><control><sourceid>jstage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_14789_jmj_62_463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>article_jmj_62_6_62_463_article_char_en</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4093-12196952d19c3b459473ea7aa49142cee02c19dcf9ab3a18d084f9f962e6fd3f3</originalsourceid><addsrcrecordid>eNo9UF1L7DAQLXIFRX3yD-RdujdfmzYPl8tS_FhQFFafQ0ynbkqbLEla2H9v1lVfZobDmXNmTlFcE7wgvKrl337sF4IuuGAnxTkldV1SQsWfr7kqZcWqs-Iqxh5jTCWWRPDzYnrxMfkdBJ3sDGjV9tOsXULNFkafthnf7dF63AU_Q0SbKcx21gOyDm2S_gC0XqPGD96hRjsDAf1HK_QSsqCLNu3RxvgA6Ekns7XuA62cHvbRxsvitNNDhKvvflG83d2-Ng_l4_P9ulk9loZjyUpCiRRySVsiDXvnS8krBrrSmkvCqQHA1BDZmk7qd6ZJ3eKad7KTgoLoWtaxi-LmqGuCjzFAp3bBjjrsFcHqKzSVQ1OCqhxaZt8f2SO01uj81WAdqN5PId8dVdeSfnIJFMVEKIwFxYe2VDhv51IRRjLID0r_jkp9PKT066pDsmaAH1Px7fyLm60OChz7BCp_jXQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Postoperative Adjuvant Chemotherapy Improves Survival in Stage II Colon Cancer ? A Propensity Score Matching Analysis</title><source>J-STAGE Free</source><creator>SUGIMOTO, KIICHI ; SAKAMOTO, KAZUHIRO ; NIWA, KOICHIRO ; ISHIYAMA, SHUN ; KAMIYAMA, HIROHIKO ; KOMIYAMA, HIROMITSU ; TAKAHASHI, MAKOTO ; KOJIMA, YUTAKA ; GOTO, MICHITOSHI ; TOMIKI, YUICHI</creator><creatorcontrib>SUGIMOTO, KIICHI ; SAKAMOTO, KAZUHIRO ; NIWA, KOICHIRO ; ISHIYAMA, SHUN ; KAMIYAMA, HIROHIKO ; KOMIYAMA, HIROMITSU ; TAKAHASHI, MAKOTO ; KOJIMA, YUTAKA ; GOTO, MICHITOSHI ; TOMIKI, YUICHI ; Juntendo University Faculty of Medicine ; Department of Coloproctological Surgery</creatorcontrib><description>Objective: The use of postoperative adjuvant chemotherapy (POAC) after surgery for patients with stage II colon cancer remains controversial. The current study was conducted to investigate the effectiveness of POAC using propensity score (PS) matching analysis based on prognostic factors.Materials: Two hundred and nineteen patients with stage II colon cancer who underwent surgery with curative intent between 1995 and 2005 were enrolled.Methods: PS matching analysis was used to adjust for differences in clinicopathological severity between the patients with and without POAC.Results: Before PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.76, 95%CI; 0.40-1.45, p=0.41) or cancer-specific survival (Hazard ratio=0.52, 95%CI; 0.22-1.19, p=0.12). After PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.55, 95%CI; 0.23-1.23, p=0.15) or cancer-specific survival (Hazard ratio=0.46, 95%CI; 0.16-1.18, p=0.11).Conclusion: The one-to-one pair PS matching successfully balanced the clinicopathological factors between the patients with and without POAC. The PS matching analysis demonstrated no significant difference in survival in the patients with stage II colon cancer.</description><identifier>ISSN: 2187-9737</identifier><identifier>EISSN: 2188-2126</identifier><identifier>DOI: 10.14789/jmj.62.463</identifier><language>eng</language><publisher>The Juntendo Medical Society</publisher><subject>5-FU ; postoperative adjuvant chemotherapy ; prognostic factor ; propensity score matching analysis ; stage II colon cancer</subject><ispartof>Juntendo Medical Journal, 2016, Vol.62(6), pp.463-471</ispartof><rights>2016 The Juntendo Medical Society. This is an open access article distributed under the terms of Creative Commons Attribution License (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original source is properly credited.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c4093-12196952d19c3b459473ea7aa49142cee02c19dcf9ab3a18d084f9f962e6fd3f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,1883,4024,27923,27924,27925</link.rule.ids></links><search><creatorcontrib>SUGIMOTO, KIICHI</creatorcontrib><creatorcontrib>SAKAMOTO, KAZUHIRO</creatorcontrib><creatorcontrib>NIWA, KOICHIRO</creatorcontrib><creatorcontrib>ISHIYAMA, SHUN</creatorcontrib><creatorcontrib>KAMIYAMA, HIROHIKO</creatorcontrib><creatorcontrib>KOMIYAMA, HIROMITSU</creatorcontrib><creatorcontrib>TAKAHASHI, MAKOTO</creatorcontrib><creatorcontrib>KOJIMA, YUTAKA</creatorcontrib><creatorcontrib>GOTO, MICHITOSHI</creatorcontrib><creatorcontrib>TOMIKI, YUICHI</creatorcontrib><creatorcontrib>Juntendo University Faculty of Medicine</creatorcontrib><creatorcontrib>Department of Coloproctological Surgery</creatorcontrib><title>Postoperative Adjuvant Chemotherapy Improves Survival in Stage II Colon Cancer ? A Propensity Score Matching Analysis</title><title>Juntendo Iji Zasshi = Juntendo Medical Journal</title><addtitle>Juntendo Medical Journal</addtitle><description>Objective: The use of postoperative adjuvant chemotherapy (POAC) after surgery for patients with stage II colon cancer remains controversial. The current study was conducted to investigate the effectiveness of POAC using propensity score (PS) matching analysis based on prognostic factors.Materials: Two hundred and nineteen patients with stage II colon cancer who underwent surgery with curative intent between 1995 and 2005 were enrolled.Methods: PS matching analysis was used to adjust for differences in clinicopathological severity between the patients with and without POAC.Results: Before PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.76, 95%CI; 0.40-1.45, p=0.41) or cancer-specific survival (Hazard ratio=0.52, 95%CI; 0.22-1.19, p=0.12). After PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.55, 95%CI; 0.23-1.23, p=0.15) or cancer-specific survival (Hazard ratio=0.46, 95%CI; 0.16-1.18, p=0.11).Conclusion: The one-to-one pair PS matching successfully balanced the clinicopathological factors between the patients with and without POAC. The PS matching analysis demonstrated no significant difference in survival in the patients with stage II colon cancer.</description><subject>5-FU</subject><subject>postoperative adjuvant chemotherapy</subject><subject>prognostic factor</subject><subject>propensity score matching analysis</subject><subject>stage II colon cancer</subject><issn>2187-9737</issn><issn>2188-2126</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNo9UF1L7DAQLXIFRX3yD-RdujdfmzYPl8tS_FhQFFafQ0ynbkqbLEla2H9v1lVfZobDmXNmTlFcE7wgvKrl337sF4IuuGAnxTkldV1SQsWfr7kqZcWqs-Iqxh5jTCWWRPDzYnrxMfkdBJ3sDGjV9tOsXULNFkafthnf7dF63AU_Q0SbKcx21gOyDm2S_gC0XqPGD96hRjsDAf1HK_QSsqCLNu3RxvgA6Ekns7XuA62cHvbRxsvitNNDhKvvflG83d2-Ng_l4_P9ulk9loZjyUpCiRRySVsiDXvnS8krBrrSmkvCqQHA1BDZmk7qd6ZJ3eKad7KTgoLoWtaxi-LmqGuCjzFAp3bBjjrsFcHqKzSVQ1OCqhxaZt8f2SO01uj81WAdqN5PId8dVdeSfnIJFMVEKIwFxYe2VDhv51IRRjLID0r_jkp9PKT066pDsmaAH1Px7fyLm60OChz7BCp_jXQ</recordid><startdate>2016</startdate><enddate>2016</enddate><creator>SUGIMOTO, KIICHI</creator><creator>SAKAMOTO, KAZUHIRO</creator><creator>NIWA, KOICHIRO</creator><creator>ISHIYAMA, SHUN</creator><creator>KAMIYAMA, HIROHIKO</creator><creator>KOMIYAMA, HIROMITSU</creator><creator>TAKAHASHI, MAKOTO</creator><creator>KOJIMA, YUTAKA</creator><creator>GOTO, MICHITOSHI</creator><creator>TOMIKI, YUICHI</creator><general>The Juntendo Medical Society</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2016</creationdate><title>Postoperative Adjuvant Chemotherapy Improves Survival in Stage II Colon Cancer ? A Propensity Score Matching Analysis</title><author>SUGIMOTO, KIICHI ; SAKAMOTO, KAZUHIRO ; NIWA, KOICHIRO ; ISHIYAMA, SHUN ; KAMIYAMA, HIROHIKO ; KOMIYAMA, HIROMITSU ; TAKAHASHI, MAKOTO ; KOJIMA, YUTAKA ; GOTO, MICHITOSHI ; TOMIKI, YUICHI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4093-12196952d19c3b459473ea7aa49142cee02c19dcf9ab3a18d084f9f962e6fd3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>5-FU</topic><topic>postoperative adjuvant chemotherapy</topic><topic>prognostic factor</topic><topic>propensity score matching analysis</topic><topic>stage II colon cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SUGIMOTO, KIICHI</creatorcontrib><creatorcontrib>SAKAMOTO, KAZUHIRO</creatorcontrib><creatorcontrib>NIWA, KOICHIRO</creatorcontrib><creatorcontrib>ISHIYAMA, SHUN</creatorcontrib><creatorcontrib>KAMIYAMA, HIROHIKO</creatorcontrib><creatorcontrib>KOMIYAMA, HIROMITSU</creatorcontrib><creatorcontrib>TAKAHASHI, MAKOTO</creatorcontrib><creatorcontrib>KOJIMA, YUTAKA</creatorcontrib><creatorcontrib>GOTO, MICHITOSHI</creatorcontrib><creatorcontrib>TOMIKI, YUICHI</creatorcontrib><creatorcontrib>Juntendo University Faculty of Medicine</creatorcontrib><creatorcontrib>Department of Coloproctological Surgery</creatorcontrib><collection>CrossRef</collection><jtitle>Juntendo Iji Zasshi = Juntendo Medical Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SUGIMOTO, KIICHI</au><au>SAKAMOTO, KAZUHIRO</au><au>NIWA, KOICHIRO</au><au>ISHIYAMA, SHUN</au><au>KAMIYAMA, HIROHIKO</au><au>KOMIYAMA, HIROMITSU</au><au>TAKAHASHI, MAKOTO</au><au>KOJIMA, YUTAKA</au><au>GOTO, MICHITOSHI</au><au>TOMIKI, YUICHI</au><aucorp>Juntendo University Faculty of Medicine</aucorp><aucorp>Department of Coloproctological Surgery</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Postoperative Adjuvant Chemotherapy Improves Survival in Stage II Colon Cancer ? A Propensity Score Matching Analysis</atitle><jtitle>Juntendo Iji Zasshi = Juntendo Medical Journal</jtitle><addtitle>Juntendo Medical Journal</addtitle><date>2016</date><risdate>2016</risdate><volume>62</volume><issue>6</issue><spage>463</spage><epage>471</epage><pages>463-471</pages><issn>2187-9737</issn><eissn>2188-2126</eissn><abstract>Objective: The use of postoperative adjuvant chemotherapy (POAC) after surgery for patients with stage II colon cancer remains controversial. The current study was conducted to investigate the effectiveness of POAC using propensity score (PS) matching analysis based on prognostic factors.Materials: Two hundred and nineteen patients with stage II colon cancer who underwent surgery with curative intent between 1995 and 2005 were enrolled.Methods: PS matching analysis was used to adjust for differences in clinicopathological severity between the patients with and without POAC.Results: Before PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.76, 95%CI; 0.40-1.45, p=0.41) or cancer-specific survival (Hazard ratio=0.52, 95%CI; 0.22-1.19, p=0.12). After PS matching analysis significant survival benefits from POAC were not recognized for recurrence-free survival (Hazard ratio=0.55, 95%CI; 0.23-1.23, p=0.15) or cancer-specific survival (Hazard ratio=0.46, 95%CI; 0.16-1.18, p=0.11).Conclusion: The one-to-one pair PS matching successfully balanced the clinicopathological factors between the patients with and without POAC. The PS matching analysis demonstrated no significant difference in survival in the patients with stage II colon cancer.</abstract><pub>The Juntendo Medical Society</pub><doi>10.14789/jmj.62.463</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2187-9737
ispartof Juntendo Medical Journal, 2016, Vol.62(6), pp.463-471
issn 2187-9737
2188-2126
language eng
recordid cdi_crossref_primary_10_14789_jmj_62_463
source J-STAGE Free
subjects 5-FU
postoperative adjuvant chemotherapy
prognostic factor
propensity score matching analysis
stage II colon cancer
title Postoperative Adjuvant Chemotherapy Improves Survival in Stage II Colon Cancer ? A Propensity Score Matching Analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T18%3A08%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Postoperative%20Adjuvant%20Chemotherapy%20Improves%20Survival%20in%20Stage%20II%20Colon%20Cancer%20?%20A%20Propensity%20Score%20Matching%20Analysis&rft.jtitle=Juntendo%20Iji%20Zasshi%20=%20Juntendo%20Medical%20Journal&rft.au=SUGIMOTO,%20KIICHI&rft.aucorp=Juntendo%20University%20Faculty%20of%20Medicine&rft.date=2016&rft.volume=62&rft.issue=6&rft.spage=463&rft.epage=471&rft.pages=463-471&rft.issn=2187-9737&rft.eissn=2188-2126&rft_id=info:doi/10.14789/jmj.62.463&rft_dat=%3Cjstage_cross%3Earticle_jmj_62_6_62_463_article_char_en%3C/jstage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true